Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 465 - 472 of 12007 results
First CRISPR-Cas9 Drug Monetised in Spate of Big-Money Royalty Transactions
November 12, 2024| News
Trump's Selection of Zeldin to Head EPA Draws Surprise, Little Hope of Avoiding Deregulation
November 12, 2024| News
The Federal Circuit Swings the Door to Anti-Suit Injunctions Back Open
November 8, 2024| Blog| Viewpoint
Can a beneficiary serve as a witness in a will contest without losing their inheritance? The Massachusetts Appeals Court says yes.
November 8, 2024| Blog| Viewpoint
Why companies may want to accelerate marketing approval for their patented drugs in Canada
November 8, 2024| Blog| Viewpoint
2024 Post-Election Analysis
November 8, 2024| Article| Viewpoint
Mitch Frazer Awarded King Charles III Coronation Medal
November 8, 2024| News
Toronto’s Top Lawyers for 2024
November 8, 2024| News
News & Press Releases
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.
Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|
Health Law Diagnosed: PBM Update Spring 2025
June 10, 2025| Podcast|